Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CELZ with free AI briefings, catalyst countdowns, and dilution alerts.

CELZ · CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$6.8M Cash on Hand
13.1mo Cash Runway
Follow CELZ by email Get an email when CELZ reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CELZ, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Remimazolam Anesthesia, Intravenous Phase 3 · NCT03661489 Completed
C Peptide Diabetes Mellitus, Type 1 Phase 2 · NCT00278980 Completed
CELZ-201 Administration Type 1 Diabetes Phase 1/2 · NCT05626712 Recruiting
CELZ-201-DDT Chronic Low-back Pain Phase 1/2 · NCT06053242 Active not recruiting

Also used in these trials (approved or third-party drugs, not CELZ's own candidates): Propofol.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CELZ holds $6.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.6M/quarter from operations, an estimated runway of 13.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 48 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CELZ files for a raise →

👥 Who Owns CELZ

Insiders 13.6% Institutions (17 holders) 5.9% Public and other holders 80.5%
HolderTypeShares% of sharesAs of
Timothy Warbington
President & CEO, Director, 10% owner
Insider 1,034,904 13.62% 2026-09-24
Michael H. Finger
Director
Insider 351 0.00% 2025-02-18

Share count 7,597,557 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CELZ picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CELZ and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.